Horsburgh B C, Hubinette M M, Qiang D, MacDonald M L, Tufaro F
NeuroVir Inc, Vancouver, BC, Canada.
Gene Ther. 1999 May;6(5):922-30. doi: 10.1038/sj.gt.3300887.
Herpes simplex virus (HSV) is a new platform for gene therapy. We cloned the human herpesvirus HSV-1 strain F genome into a bacterial artificial chromosome (BAC) and adapted chromosomal gene replacement technology to manipulate the viral genome. This technology exploits the power of bacterial genetics and permits generation of recombinant viruses in as few as 7 days. We utilized this technology to delete the viral packaging/cleavage (pac) sites from HSV-BAC. HSV-BAC DNA is stable in bacteria and the pac-deleted HSV-BAC (p45-25) is able to package amplicon plasmid DNA as efficiently as a comparable pac-deleted HSV cosmid set when transfected into mammalian cells. Moreover, the utility of bacterial gene replacement is not limited to HSV, since most herpesviruses can be cloned as BACs. Thus, this technology will greatly facilitate genetic manipulation of all herpesviruses for their use as research tools or as vectors in gene therapy.
单纯疱疹病毒(HSV)是一种用于基因治疗的新平台。我们将人类疱疹病毒HSV-1株F基因组克隆到细菌人工染色体(BAC)中,并采用染色体基因置换技术来操纵病毒基因组。该技术利用了细菌遗传学的优势,可在短短7天内产生重组病毒。我们利用此技术从HSV-BAC中删除了病毒包装/切割(pac)位点。HSV-BAC DNA在细菌中稳定,当转染到哺乳动物细胞中时,缺失pac的HSV-BAC(p45-25)包装扩增子质粒DNA的效率与可比的缺失pac的HSV黏粒组一样高。此外,细菌基因置换的效用不仅限于HSV,因为大多数疱疹病毒都可以克隆为BAC。因此,这项技术将极大地促进所有疱疹病毒的基因操作,使其用作研究工具或基因治疗载体。